Search Result

Results for "

adenomas

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (1) Akt (1) Apoptosis (6) Atg8/LC3 (3) Autophagy (3) Bcl-2 Family (1) Biochemical Assay Reagents (2) Carbonic Anhydrase (2) Carboxylesterase (CES) (2) Caspase (3) COX (2) Cytochrome P450 (1) Endogenous Metabolite (1) Environmental Pollutants (2) Farnesyl Transferase (1) Fungal (2) GLUT (2) Herbicide (1) Insecticide (1) Interleukin Related (1) JAK (3) Mitosis (1) NF-κB (1) NOD-like Receptor (NLR) (2) Notch (1) p38 MAPK (1) p62 (3) PARP (1) PERK (1) PI3K (1) Progesterone Receptor (1) Ras (1) Reactive Oxygen Species (ROS) (3) Reference Standards (4) Somatostatin Receptor (5) STAT (3) VEGFR (1) Zinc Finger Protein (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (3) Endocrinology (7) Inflammation/Immunology (3) Metabolic Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0127

Yohimbine Hydrochloride 15+ Cited Publications	Adrenergic Receptor	Endocrinology
Yohimbine hydrochloride is an alpha-2 renal adenomatase receptor inhibitor, blocking pre- and post-contact alpha-2 renal adenomatase receptors, causing the release of renal adenoma and multiple sclerosis.

HY-N0921

Dihydromethysticin (+)-Dihydromethysticin	Carboxylesterase (CES) NOD-like Receptor (NLR) Apoptosis	Cancer
Dihydromethysticin is an orally active natural active ingredient. Dihydromethysticin can be extracted from Piper methysticum. Dihydromethysticin inhibits carboxylesterase 1 (K_i = 68.2 μM) and CYP2A5. Dihydromethysticin upregulates NLRC3 and induces Apoptosis. Dihydromethysticin exhibits anticancer activity against colorectal cancer and lung adenoma .

HY-139838

Epyrifenacil	Herbicide	Others Cancer
Epyrifenacil is a protoporphyrinogen oxidase (PPO) inhibiting herbicide, potently targeting the PPO₂isoform from weeds such as Amaranthus palmeri with an IC₅₀ of 0.637 nM. Epyrifenacil also inhibits liver mitochondrial PPO across species, with IC₅₀ values of 2.2 nM (mouse), 2.6 nM (rat), 12.1 nM (rabbit), 7.6 nM (dog), and 10.2 nM (human). Epyrifenacil induces liver tumor development in mice. Epyrifenacil can be used for weed control, and also used as a tool compound in toxicological research to study the mechanism of PPO inhibition, chemical-induced hepatotoxicity, and the mode of action of non-genotoxic carcinogens in rodents ^[3].

HY-A0277

Cyproconazole	Environmental Pollutants Fungal	Others
Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .

HY-P1959

Lanreotide BIM 23014	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome .

HY-P1959A

Lanreotide acetate BIM 23014 acetate	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome .

HY-15873A

FTI 276 TFA	Farnesyl Transferase Ras p38 MAPK	Cancer
FTI 276 TFA is a farnesyltransferase (FTase) inhibitor with an IC₅₀ of 0.5 nM, and it exhibits selectivity for FTase over geranylgeranyltransferase I (GGTase I). FTI 276 TFA blocks the farnesylation of H-Ras and K-Ras4B, causes inactive Ras-Raf complexes to accumulate in the cytoplasm, and inhibits constitutive MAPK activation. FTI 276 TFA reduces the number, incidence and volume of tumors, and restricts the growth of tumors expressing activated K-ras. FTI 276 TFA can be used in research related to pulmonary adenoma .

HY-Y0496

1,4-Dichlorobenzene	Insecticide Environmental Pollutants Mitosis	Cancer
1,4-Dichlorobenzene is a non-genotoxic, orally active mitogenic/tumor-promoting carcinogen that is also widely used as a dye, resin intermediate, and deodorant, moth repellent/insecticide. 1,4-Dichlorobenzene induces liver tumors in mice and promotes the growth of spontaneous precancerous lesions, but shows no liver tumor-inducing activity in F344 rats. Exposure to 1,4-dichlorobenzene leads to elevated leukocyte counts, serum alanine aminotransferase, and blood urea nitrogen levels. Due to the hepatotoxic characteristics, 1,4-Dichlorobenzene is applicable to liver cancer-related research .

HY-16726

Polmacoxib CG100649	COX Carbonic Anhydrase	Cancer
Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC₅₀ around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .

HY-149276

SLC26A3-IN-2 1 Publications Verification	GLUT	Metabolic Disease
SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC₅₀=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea .

HY-B1341

Norethynodrel Enidrel; SC-4642; NSC 15432	Endogenous Metabolite Progesterone Receptor	Cancer
Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma .

HY-13559

Atiprimod Azaspirane ; SKF 106615-12; SKF 106615A12	STAT Apoptosis Autophagy Reactive Oxygen Species (ROS) Caspase Bcl-2 Family p62 Atg8/LC3 PARP NF-κB PERK JAK	Cardiovascular Disease Inflammation/Immunology Cancer
Atiprimod (Azaspirane) is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) .

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared withOctreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-A0277R

Cyproconazole (Standard)	Reference Standards Fungal	Others
Cyproconazole (Standard) is the analytical standard of Cyproconazole. This product is intended for research and analytical applications. Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .

HY-13559A

Atiprimod dimaleate Azaspirane dimaleate; SKF 106615-12 dimaleate; SKF 106615A12 dimaleate	STAT Apoptosis Caspase Interleukin Related Autophagy Reactive Oxygen Species (ROS) Atg8/LC3 p62 JAK	Cardiovascular Disease Inflammation/Immunology Cancer
Atiprimod (Azaspirane) (dimaleate) is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) .

HY-110102

Atiprimod hydrochloride Azaspirane hydrochloride; SKF 106615-12 hydrochloride; SKF 106615	JAK STAT Apoptosis Autophagy Reactive Oxygen Species (ROS) Caspase Atg8/LC3 p62	Cardiovascular Disease Inflammation/Immunology Cancer
Atiprimod (Azaspirane) hydrochloride is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) .

HY-131923

DAPM	Notch	Cancer
DAPM is a Notch pathway inhibitor with anticancer activity and antiproliferative effects. DAPM effectively inhibits tubular adenoma development by inhibiting cell proliferation and inducing the expression of Krüppel-like factor 4 (KLF4) and p21 in human colon cancer cells .

HY-16726R

Polmacoxib (Standard) CG100649 (Standard)	Reference Standards COX Carbonic Anhydrase	Cancer
Polmacoxib (Standard) is the analytical standard of Polmacoxib. This product is intended for research and analytical applications. Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC₅₀ around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .

HY-169475

1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin 1,2,3,7,8,9-HxCDD	Biochemical Assay Reagents	Cancer
1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin (1,2,3,7,8,9-HxCDD) is a polychlorinated dibenzodioxin. 1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin combined with 1,2,3,6,7,8-hexachlorodibenzo-p-dioxin induces the formation of liver adenomas or carcinomas in rats .

HY-N0127R

Yohimbine Hydrochloride (Standard)	Reference Standards Adenosine Receptor	Endocrinology
Yohimbine Hydrochloride Standard is an alpha-2 renal adenomatase receptor inhibitor, blocking pre- and post-contact alpha-2 renal adenomatase receptors, causing the release of renal adenoma and multiple sclerosis.

HY-162574

CYP11B2-IN-2	Cytochrome P450	Cancer
CYP11B2-IN-2 (Compound 10k) is an inhibitor for enzyme aldosterone synthase CYP11B2 with an IC₅₀ of 0.3 nM. CYP11B2-IN-2 CYP11B-IN-2 is labeled with 18F and can be used as a positron emission tomography (PET) tracer for the diagnosis of primary aldosteronism .

HY-147152

1-Myristoyl-3-chloropropanediol	Biochemical Assay Reagents	Others
1-Myristoyl-3-chloropropanediol is a 3-monochloropropanediol (3-MCPD) fatty acid ester. 3-MPCD causes nephropathy and tubular hyperplasia and adenomas by chronic oral administration; also reduces fertility, or provokes infertility in rats and suppresses the immune function .

HY-122927

Symphytine	Others	Cancer
Symphytine is a pyrrolizidine alkaloid isolated from Symphytum officinale and has carcinogenicity .

HY-P1959B

Lanreotide diTFA BIM 23014 diTFA	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome .

HY-N0921R

Dihydromethysticin (Standard) (+)-Dihydromethysticin (Standard)	Reference Standards Carboxylesterase (CES) NOD-like Receptor (NLR) Apoptosis	Cancer
Dihydromethysticin (Standard) is the analytical standard of Dihydromethysticin (HY-N0921). This product is intended for research and analytical applications. Dihydromethysticin is an orally active natural active ingredient. Dihydromethysticin can be extracted from Piper methysticum. Dihydromethysticin inhibits carboxylesterase 1 (K_i = 68.2 μM) and CYP2A5. Dihydromethysticin upregulates NLRC3 and induces Apoptosis. Dihydromethysticin exhibits anticancer activity against colorectal cancer and lung adenoma .

HY-149802

SLC26A3-IN-1	GLUT	Metabolic Disease
SLC26A3-IN-1 is an inhibitor of anion exchanger protein SLC26A3 (IC₅₀=340 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea .

HY-P992086

Anti-Mouse VEGF Antibody (G6-31)	VEGFR	Cancer
Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1 .

HY-180281

PLAGL2-IN-1	Zinc Finger Protein Apoptosis PI3K Akt	Cancer
PLAGL2-IN-1 is a inhibitor of pleiomorphic adenoma-like protein 2 (PLAGL2) with a K_d of 2.23 µM. PLAGL2-IN-1 suppresses PLAGL2 transcriptional activity, induces G0/G1 cell cycle arrest, and apoptosis, thereby inhibiting hepatocellular carcinoma (HCC) cell proliferation. PLAGL2-IN-1 disrupts extracellular matrix organization and suppresses the PI3K-AKT pathway by reducing AKT phosphorylation. PLAGL2-IN-1 inhibits tumor growth in an HCCLM3 xenograft mouse model. PLAGL2-IN-1 can be used for the research of HCC .

Cat. No.	Product Name

HY-L188

Anti-Brain Cancer Compound Library	2,056 compounds
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,056 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

Anti-Brain Cancer Compound Library

2,056 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 2,056 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

Cat. No.	Product Name	Target	Research Area